Greyledge Technologies was established by Dr. David C. Karli to meet emerging physician and patient demands to facilitate and utilize mechanisms of natural healing to augment and/or support treatment of disease. Dr. Karli also recognized the deficiency in product quality in the growing field and that Physicians didn’t know exactly what they were putting into their patients. In order to meet these first initiative, Greyledge has developed novel, manual laboratory-based methods to process autologous whole blood and bone marrow tissues to produce biologic preparations that are quality and quantity controlled to create a better product and higher level of research and development to advance the field of cellular therapies.